HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
about
Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaTalin regulates moesin-NHE-1 recruitment to invadopodia and promotes mammary tumor metastasis.Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levelsThe histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Rituximab resistance.Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population.Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma.Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.Use of class I histone deacetylase inhibitor romidepsin in combination regimensThe novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Combination strategies to enhance antitumor ADCC.Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy ResponseEntinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma.Early relapse in a case of primary bone marrow diffuse large B-cell lymphoma treated with rituximab-CHOP.Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma.Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
P2860
Q28486745-B10D36C5-ACD2-4E47-BA31-92041049F81BQ33731231-529C828F-41AF-4FB4-98F5-A4823E6597C3Q33808800-4346C9EC-CDF6-4E28-B248-14F40546C7F4Q33913962-30140B3D-5309-4696-9072-1AC48BDE86B6Q34062453-825DF767-2BFE-4A8A-9ABC-B77338890BACQ34662212-F305C556-6FE1-4063-9C9E-F81F337039B2Q34700655-3B022CB5-A1B2-4449-8AE4-38781D7F7BDBQ35041270-FC64C95A-9F0B-43C8-97BF-37C4E4353087Q35741591-1EC20DD0-BA3D-4B77-8524-DAA62AC55E50Q36046580-CCAF443D-AA68-47E2-AFAD-AC4135C5D0A4Q36528137-B3AA649F-A81E-426B-9167-AE07C9C6D2A7Q36719078-0C8D0219-336D-4803-966E-97540EC09AA0Q36758025-7D54F0FA-1BB6-4E78-AAA1-4D1EDEED2599Q36808210-316175A9-6E0F-48B1-9933-B07C5CBA7B7BQ37107439-6F1DFF0D-C0C4-45B0-913C-15DF3D1F2B0DQ37132187-88CDEDE6-3C43-4653-B4E7-F3BD5F247F18Q37146688-7D5838CF-0A80-4C2B-B8DF-F6B75A8DD0E0Q37178611-71AD1918-B64F-4019-A12A-5811C5178F8DQ37650735-DD849A2E-2156-4556-9A5C-DA680C9C9E30Q38014085-3BBD1B7E-2D6D-4792-9DC2-6FD40B6A607CQ38132359-20DA34D1-D1B9-4ADD-94EB-6AF0FFDFB03EQ38273851-A655F511-90EF-4289-9C80-A994A26BC1B3Q38573785-E66AFBA1-BB0F-4E61-80F6-39FF2BBE769FQ38694036-37BB4C82-E0F6-472F-B93A-C099F34F2BAEQ38896113-6F8D498B-784E-4537-9BB6-94C0282D2744Q38906418-1D71F207-A2CE-47A6-8A58-97704B6D84AFQ39007207-6645B2A5-4147-49BF-9AB6-F2F8764BD853Q39013616-BA984F2F-B935-487B-B1A5-B36B6EA36955Q39061338-A6A48C0C-E964-41A1-AC0A-B704047C697BQ39128700-43632EC6-1D49-42C1-8AB3-C7E9F9B06F8FQ39248784-1A799A81-C9E1-4F47-B09B-872AD2B4CFB1Q40059586-7F401C3F-138E-4E78-9FA6-C37F43C9CEFCQ40063229-B6A248A6-7B1F-41E7-A2CC-3147130FFE9AQ40603238-EBCF8FB8-4116-4B04-B1A6-7E8C3FB4F45AQ41844423-021184EF-800D-43DC-B33C-572E27D50CC8Q43269281-4A0B5E02-41A0-4F4C-BF1D-1271DCB86AD5Q47951320-6FB79395-CAD2-4D1B-A6DC-86CF2230B9E5Q52931736-7827DEB2-4774-4B1B-93DD-6C6B2B529018Q55052715-6E185151-718E-4636-A93D-68CC75F074BB
P2860
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@en
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@nl
type
label
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@en
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@nl
prefLabel
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@en
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@nl
P2093
P2860
P356
P1433
P1476
HDAC inhibitors augment cytoto ...... expression on lymphoma cells.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.157
P577
2010-08-05T00:00:00Z
P5875
P6179
1017826637